| European Case Law Identifier: | ECLI:EP:BA:2015:T205913.20151207 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 07 December 2015 | ||||||||
| Case number: | T 2059/13 | ||||||||
| Application number: | 06015782.3 | ||||||||
| IPC class: | A61K 31/00 A61K 31/496 A61K 45/06 A61P 25/24 A61P 25/18 A61P 25/28 A61P 25/16 A61P 25/06 A61P 25/30 A61P 15/00 A61P 3/04 A61P 1/08 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Substituted carbostyril derivatives as 5-HT 1A receptor subtype agonists for the treatment of bipolar disorder | ||||||||
| Applicant name: | OTSUKA PHARMACEUTICAL CO., LTD. | ||||||||
| Opponent name: | STADA Arzneimittel AG Sanovel Ilaç Sanayi ve Ticaret A.S. Hexal AG Teva Pharmaceutical Industries Ltd. Actavis Group PTC EHF PENTAFARMA S.A. CHEMO IBERICA, S.A. Helm AG |
||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Late-filed documents - admitted (no) Sufficiency of disclosure of further medical use - (no) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t132059eu1.html
Date retrieved: 17 May 2021